<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/PHFP-8573 " scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> sterility</p><p><b>Protocol Name:</b> NCL Method STE-3: Detection of Mycoplasma Contamination in Nanoparticle Formulations</p><p><b>Protocol Abbreviation:</b> STE-3</p><p><b>Protocol Version:</b> 3<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/PHFP-8573 >http://dx.doi.org/10.17917/PHFP-8573 </a></p><p><b>Protocol File:</b> protocols/20240409_12-11-05-819_NCL_Method_STE-3.pdf<p><b>File Title:</b> STE-3</p><p><b>Description:</b></b> Mycoplasma is a microorganism that lacks a nucleus and a cell wall which makes it unaffected by many antibiotics. Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when deemed necessary. The types of nanoparticle formulations generally tested for mycoplasma contamination include those that incorporate a component derived from an animal or hybridoma cultures.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>